The B2B platform for the best purchasing descision. Identify and compare relevant B2B manufacturers, suppliers and retailers
Filter
Locations
Result types
Type of company
Select company type
Industries
Select industry
Company status
Select company status preset
Number of employees
Min.
Max.
Founding year
Lock keywords
Exclude keywords
Optional keywords
Berkeley, United States
101-250 Employees
2011
To deliver on our mission, we are advancing clinical-stage allogeneic CAR-T cell therapies for patients with hematologic malignancies. We are a clinical-stage biopharmaceutical company focused on developing transformative genome-edited allogeneic cell therapies for devastating human diseases. We are developing allogeneic, or off-the-shelf, CAR-T and CAR-NK cell therapies from healthy donor cells to address the limitations of currently approved therapies. Caribou is a clinical-stage biopharmaceutical company, founded by pioneers in CRISPR genome editing. We believe that allogeneic cell therapies have the potential to meet significant unmet needs for patients. Rachel is a co-founder of Caribou Biosciences and has been its president and chief executive officer and a director since the company’s inception in 2011. Steve is the chief scientific officer of Caribou Biosciences responsible for the company’s therapeutic discovery, research, translational, and development activities. Tim is the chief technology officer of Caribou Biosciences and is responsible for the company’s technical operations strategy and execution, including seamless integration and alignment with Caribou’s corporate strategy.
+
Featured
CAR-T cell therapy platform
... CAR-T cell therapy platform | Caribou ...
London, United Kingdom
11-50 Employees
1960
With over 2,800 members worldwide, we are the largest UK haematology organisation and the only society to cover all aspects of the specialty. LeadingBridging the gap between research and practice, our guidelines raise the standards of clinical and patient care. The chief ways that BSH acts on its mission are:. We bring committed volunteers together to support our purpose to champion and strengthen haematology practice.
+
Featured
Dasatinib ‘pauses’ CAR T cell therapy activity
... have shown that an existing leukaemia drug is able to temporarily ‘pause’ the activity of CAR T cell therapy in mice – a finding which could pave the way for better management of the treatment’s side effects. The research, published in Science Translational Medicine, found that ...
Newton, United States
1-10 Employees
2016
Prior to joining AffyImmune, Dawn led the entire early development Cell Therapy portfolio for clinical trials at BMS. AffyImmune is harnessing the power of the body’s own immune system to seek and destroy cancer cells by overcoming the immunotherapy challenges for solid tumors. AffyImmune’s proprietary “Tune & Track” technology enhances the ability of a patient’s own immune cells to attack and destroy solid tumors, while avoiding damage to normal cells and tissues. Matt has over 25 years of industry experience spanning process development and manufacturing, strategy consulting, business development, and operations. Pete brings over 15 years of extensive experience in Manufacturing and CMC Product Development to AffyImmune. Dawn is a seasoned Clinical Operations leader, with over 25 years of industry experience. Arya has twenty-five years of experience at building and leading Process Development, Global Manufacturing, and Global Quality organizations at companies including Novartis, Biogen, Alnylam, and Invivyd. Josh brings 10 years of accounting and finance experience to AffyImmune, including 4 years of increasing responsibility at Affy.
+
Featured
Affyimmune – Realizing CAR T-Cell Therapies’ Full Potential
... Tune & Track Affinity Tuned CAR T Cells for Solid Tumors Unlocking the Full Potential of CAR T Cell Therapies AffyImmune is harnessing the ...
Suzhou City, China
51-100 Employees
2017
We are developing a rich clinical-stage pipeline to unlock the long-held promise of CAR-T cell therapies. Gracell Biotechnologies is a global clinical-stage biopharmaceutical company dedicated to discovering and developing innovative and highly efficacious cell therapy. Dr Xie has over 18 years of finance and investment experience in leading healthcare investment organizations. Xie served as the President of Fosun Healthcare Holdings and Chief Representative of Fosun, New York. Xie co-founded and served as Portfolio Manager of Locust Walk Capital. Gracell is developing cell therapy that deliver fast, deep and durable responses for cancer and autoimmune disease patients. Our autologous platform producing CAR-T cell therapies that utilize next-day manufacturing to deliver younger, less exhausted T cells with enhanced activities.
+
Featured
Pioneering the Next Generation of CAR-T Cell Therapies
... We aim to disrupt conventional approaches to CAR-T cell therapies with our pioneering FasTCAR and TruUCAR technology platforms and SMART CARTTM technology module. ...
New York, United States
1-10 Employees
2020
Kernls provides the only way for donors to connect directly with medical researchers to fund, see and share the impact of their work. Kernls helps research organizations amplify the visibility of high-priority projects by finding and fostering connections with donors from new and existing channels.
+
Featured
Attract, grow and retain large donors for medical research | Kernls
... Harris at Einstein College working on Car-T cell therapy for Non-Hodgkins lymphoma means a lot to me.” ...
Vancouver, Canada
11-50 Employees
1993
At STEMSOFT, we are passionate about building software that supports effective, timely, and data-driven manufacturing and use of cell-based therapies. STEMSOFT is a privately held company with a 27-year (and counting) track record of stability, reliability, and innovation. Clients choose STEMSOFT because of the quality of our software and our commitment to ensuring that our products continually evolve to address new science, new medicine, new regulations, and new operational requirements. STEMSOFT is a division of STEMCELL Technologies Canada Inc. Everyone at STEMSOFT has dedicated their careers to supporting the cell therapy field. STEMSOFT employs a full-time, in-house product development team. Geoff Browne joined STEMSOFT in 1996, working in software development, systems analysis, customer support, software quality assurance, implementation and training. David Barwin joined the STEMSOFT Product team in 2011 and boasts extensive experience with software development, team leadership, and agile philosophy.
+
Featured
IEC and CAR-T Cell Therapy Providers
... Software Solutions for IEC and CAR-T Cell Therapy Providers | STEMSOFT ...
Holytown, United Kingdom
11-50 Employees
2013
We are developing safer, less expensive CAR-T products which can target more cancers and save more lives. Our mission is to develop and commercialize innovative cell-based products and to treat disease, improve patient health and Quality of Life. We are committed to bringing improved medicines to patients as quickly as possible by creating efficient product development and clinical translation processes. We do this using our integrated model which drives the development of our products through preclinical testing to the clinic. TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. Established in 2014, we have expanded into 5 global locations and have grown to over 100 employees. TC BioPharm received a license from MHRA to produce gamma delta T cell therapy products at its clinical manufacturing facility near Glasgow, UK. This was an adaptive clinical trial for TC BioPharm’s autologous gamma delta T cell product for melanoma, lung and kidney cancer.
+
Featured
Home • TC BioPharm
... TC BioPharm (Nasdaq: TCBP) is a publicly traded, clinical-stage cell therapy company developing advanced allogeneic CAR-T cell therapy products for the treatment of cancer. ...
London, United Kingdom
101-250 Employees
2014
Autolus actively collaborates with healthcare professionals and various essential stakeholders to deliver gene therapies to patients. We are dedicated to engaging with individuals and organizations involved in the specific disease areas we focus on, and we continuously seek out new partnerships. We are currently enrolling for several clinical trials. Autolus is fully committed to the development of safe and effective therapies for patients and places a strong emphasis on prioritizing patient needs. Autolus applies extensive programming capabilities to develop advanced autologous T cell therapies that have the potential to deliver life-changing benefits to cancer patients and is building a fully integrated, next-generation CAR T company. Autolus is applying its extensive cell programming capability to develop a pipeline of precise, controlled and highly active products. Whilst working at Autolus you will enjoy a flexible, diverse and dynamic working environment which actively promotes creativity, leadership and teamwork – together we are ONE Autolus. Autolus is building a fully-integrated, next generation CAR T company.
+
Featured
Technology | Autolus
... Enhancing CAR T cell therapy using Fab-Based Constitutively Heterodimeric Cytokine ...
Kolkata, India
1-10 Employees
2019
CancerFax is the most trusted international patient facilitator working with top cancer hospitals in the world like MD Anderson, Danar Farber, Mayo Clinic, Memorial Sloan Kettering, Asan, Sheba, TMH, NCC Japan, Beijing Cancer Institute, Apollo, BLK, to bring you best and latest drugs and therapies. To date, CancerFax has helped hundreds of patients who are battling with cancer find best and economical treatment for themselves. CancerFax is a pioneering platform dedicated to connecting individuals facing late-stage cancers with groundbreaking cell therapies like CAR T-Cell therapy, TIL therapy, Stem cell therapy and clinical trials worldwide. CancerFax is the most trusted international patient facilitator, working with top cancer hospitals in the world like MD Anderson, Dana Farber, Mayo Clinic, Parkway Singapore, Asan, Sheba, NCC Japan, Beijing Cancer Institute, Apollo, and BLK Max to bring you the best and latest drugs and therapies. CancerFax specializes in guiding individuals through the complex process of enrolling in cancer clinical trials. Our vision is to lead the way in revolutionizing cancer treatment facilitation, ensuring every individual’s access to personalized, comprehensive, and compassionate care. CancerFax is connected to some of the world’s and the USA’s top cancer hospitals. Clinical OncologistMore than 25 Years of experience in oncology.
+
Featured
Cancer treatment abroad & CAR T-Cell therapy
... CancerFax Offers Second opinion and treatment for advanced and recurring cancer cases, haematological malignancies, latest immunotherapies, CAR T-Cell therapy and recruitment in clinical trials. Book My Free ...
United States
1-10 Employees
2006
Your Global Leader in Stem Cell Market Research. Headquartered in Washington, DC, BioInformant is the world’s first and only market research firm to specialize in the stem cell industry. When it was incorporated in 2006, BioInformant’s Founder and President, Cade Hildreth, was completing a M.S. in Biochemistry and Molecular Biology with a Specialization in Bioinformatics, the study of analyzing large quantities of biological data. Pulling together a talented team of bioinformatics experts from around Washington, DC, Cade launched BioInformant with the belief that tracking the stem cell industry had to be an easier task than analyzing billions of base pairs of DNA. 2006 was an exciting time to be entering the industry, because Shinya Yamanaka had recently discovered induced pluripotent stem cells (iPS cells), and other stem cell types like mesenchymal stem cells (MSCs), were starting to show therapeutic promise.
+
Featured
[FLASH SALE] Global Database of CAR-T Cell Therapy Companies, 2023
... This global database of CAR-T companies features all known companies worldwide who are developing chimeric antigen recepton T-cell (CAR-T) therapies. ...
Technologies which have been searched by others and may be interesting for you:
Some interesting numbers and facts about the results you have just received for CAR-T Cell Therapy
| Country with most fitting companies | United States |
| Amount of fitting manufacturers | 41 |
| Amount of suitable service providers | 35 |
| Average amount of employees | 11-50 |
| Oldest suiting company | 1960 |
| Youngest suiting company | 2020 |
20%
40%
60%
80%
CAR-T cell therapy, short for Chimeric Antigen Receptor T-cell therapy, is a form of immunotherapy that harnesses the power of an individual's immune system to fight cancer. This innovative treatment involves genetically modifying T cells, a type of white blood cell pivotal to the immune response, to produce special structures called chimeric antigen receptors (CARs) on their surface. These CARs are designed to recognize and bind to specific proteins present on the surface of cancer cells. Once the modified T cells are infused back into the patient, they are able to more effectively identify, attach to, and destroy cancer cells that bear the targeted antigen. This bespoke approach allows for the precise targeting of cancerous cells while sparing healthy ones, marking a significant advancement in oncological treatments. CAR-T cell therapy has shown remarkable success in treating certain types of blood cancers, such as acute lymphoblastic leukemia and diffuse large B-cell lymphoma, offering hope to patients who are unresponsive to conventional therapies. Its development and application represent a paradigm shift in cancer treatment, emphasizing the potential of genetic engineering and personalized medicine to combat malignancies. Nevertheless, the therapy comes with challenges, including the risk of severe immune reactions and the complexity of its production process, which are areas of ongoing research and development.
1. Highly Targeted Treatment
: CAR-T cell therapy is designed to specifically target and destroy cancer cells, minimizing damage to healthy cells. This precision significantly reduces the side effects compared to traditional chemotherapy and radiation, which can harm both cancerous and healthy cells.
2. Durable Responses
: Patients who respond to CAR-T cell therapy often experience long-lasting remissions. For some, this might translate into a cure, a benefit not typically associated with many other cancer treatments. This durability of response provides a significant advantage in the fight against cancer, particularly for those with forms of cancer that are resistant to other treatments.
3. Customizable for Each Patient
: CAR-T cell therapy is a form of personalized medicine. The treatment involves reprogramming the patient's own immune cells to fight their specific cancer, offering a customized approach not available with most other cancer therapies. This individualized treatment has the potential to be more effective since it is tailored to the unique characteristics of each patient's cancer.
4. One-time Treatment Possibility
: Unlike many cancer treatments that require ongoing sessions over months or years, CAR-T cell therapy is often administered as a single treatment. This one-time treatment can provide lasting effects, offering a less burdensome and more convenient option for patients, significantly improving their quality of life.
While evaluating the different suppliers make sure to check the following criteria:
1. Regulatory Compliance and Certifications
Ensure the supplier adheres to international standards and has the necessary approvals from regulatory bodies such as the FDA or EMA. This guarantees the therapy meets safety and efficacy requirements.
2. Manufacturing Capabilities
Assess the supplier's ability to produce CAR-T cells at scale without compromising quality. This includes their capacity for both autologous and allogeneic therapies.
3. Quality Assurance Systems
Check for robust quality management systems that ensure the consistency and purity of the CAR-T cell products. This includes regular audits and monitoring of production processes.
4. Experience and Track Record
Prioritize suppliers with a proven track record in CAR-T cell therapies, including successful treatment outcomes and patient satisfaction.
5. Research and Development Strength
The supplier should have a strong R&D foundation, demonstrating ongoing efforts to improve therapy efficacy and reduce side effects.
6. Cost and Financial Terms
Consider the cost of therapy and the supplier's financial terms. This includes evaluating the overall value offered in comparison to the price.
7. Patient Support Services
Look for suppliers that offer comprehensive patient support, including assistance with logistics, treatment planning, and follow-up care.
8. Collaborative Potential
Assess the willingness of the supplier to collaborate closely with healthcare providers for the customization of treatments and sharing of best practices.
CAR-T cell therapy, a groundbreaking approach in cancer treatment, has transcended its clinical roots to find applications across various industries, fostering unique business-to-business (B2B) collaborations. In the pharmaceutical and biotechnology sectors, companies are increasingly partnering to enhance the development and manufacturing capabilities of CAR-T cell therapies. These alliances are pivotal for sharing technical expertise, scaling production, and accelerating the time-to-market for these advanced treatments. The complexity of CAR-T cell therapy production requires specialized facilities and knowledge, making collaborations between companies with complementary strengths a strategic necessity. The research and development (R&D) field benefits from CAR-T cell therapy through partnerships between academic institutions and biotech firms. These collaborations are essential for advancing the science behind CAR-T cells, from identifying new target antigens to improving the efficacy and safety of these therapies. Such partnerships often lead to the discovery of innovative applications of CAR-T cells beyond their traditional use in oncology, including autoimmune diseases and infectious diseases. Healthcare providers also engage in B2B relationships with CAR-T cell therapy manufacturers. Hospitals and treatment centers must be equipped with the necessary infrastructure and trained staff to administer these therapies safely. Collaborations ensure that healthcare providers can offer cutting-edge treatments, while manufacturers gain valuable insights into real-world therapy outcomes and patient needs, driving further innovation and optimization of CAR-T cell therapies. In summary, CAR-T cell therapy is at the center of a web of B2B interactions spanning pharmaceuticals, biotechnology, R&D, and healthcare. Each sector leverages these partnerships to not only advance the therapeutic potential of CAR-T cells but also to navigate the complexities associated with bringing such an innovative treatment to the market and to the patient bedside.
As of the latest update, CAR-T cell therapy, a groundbreaking approach in cancer treatment that harnesses the patient's own immune system to fight cancer, has progressed to a high Technology Readiness Level (TRL), generally TRL 9. This advanced stage is attributed to the successful demonstration and deployment of CAR-T cell therapies in real-world clinical settings, particularly for certain types of blood cancers such as acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL). This achievement is underpinned by extensive clinical trials that have not only demonstrated efficacy and safety but also led to regulatory approvals by major health authorities like the FDA and EMA. The technical milestones that have been crucial in reaching this TRL include the development of sophisticated genetic engineering techniques to modify T cells, the establishment of robust manufacturing processes to produce these modified cells at scale, and the refinement of patient management protocols to mitigate therapy-related risks, such as cytokine release syndrome. The ongoing research and development efforts focus on enhancing the efficacy, broadening the applicability to other types of cancer, and reducing the costs associated with CAR-T cell therapy, indicating a commitment to further innovation within this high TRL domain.
**Short-Term:** In the immediate future, advancements in CAR-T cell therapy are expected to focus on improving the safety and efficiency of current treatments. Techniques for reducing the severity of cytokine release syndrome (CRS) and neurotoxicity, common side effects, are a priority. Additionally, researchers are working on streamlining the manufacturing process to reduce costs and increase accessibility. The introduction of off-the-shelf CAR-T cells, derived from donors rather than the patients themselves, is anticipated to begin entering clinical trials, potentially revolutionizing how quickly patients can receive this life-saving treatment. **Mid-Term:** The mid-term horizon will likely see CAR-T cell therapy expanding beyond its current primary focus on hematological malignancies to solid tumors. This expansion involves the development of novel CAR constructs and the integration of technologies such as CRISPR for more precise gene editing. Enhanced targeting mechanisms to distinguish between cancerous and healthy cells more effectively will reduce off-target effects and improve outcomes. There's also expected to be a significant push towards optimizing CAR-T cells to overcome the immunosuppressive tumor microenvironment that is characteristic of solid tumors, which has been a significant barrier to success in this area. **Long-Term:** Looking further ahead, the long-term future of CAR-T cell therapy holds the promise of fully personalized and multi-targeted treatments. Advances in artificial intelligence and machine learning will play a pivotal role in identifying novel targets and predicting patient responses to specific CAR constructs. The development of universal CAR-T cells, compatible with any patient, could become a reality, eliminating the need for individualized manufacturing. Furthermore, integrating CAR-T therapy with other treatments, such as checkpoint inhibitors and targeted therapies, will likely lead to comprehensive treatment protocols that address the complexity of cancer more effectively, potentially turning many cancers into manageable chronic diseases or achieving complete remissions.
Some interesting questions that has been asked about the results you have just received for CAR-T Cell Therapy
What are related technologies to CAR-T Cell Therapy?
Based on our calculations related technologies to CAR-T Cell Therapy are Biomedical (Red), Bioinformatics (Gold), Environmental Biotechnology (Grey), Agricultural Biotechnology (Green), Food Related Biotechnology (Yellow)
Who are Start-Ups in the field of CAR-T Cell Therapy?
Start-Ups who are working in CAR-T Cell Therapy are Kernls
Which industries are mostly working on CAR-T Cell Therapy?
The most represented industries which are working in CAR-T Cell Therapy are Health Care, Biotechnology, Science and Engineering, Professional Services, Data and Analytics
How does ensun find these CAR-T Cell Therapy Companies?
ensun uses an advanced search and ranking system capable of sifting through millions of companies and hundreds of millions of products and services to identify suitable matches. This is achieved by leveraging cutting-edge technologies, including Artificial Intelligence.
